Loading clinical trials...
Loading clinical trials...
A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-24C5 in Patients With Advanced Solid Tumors
Conditions
Interventions
LM-24C5
Locations
6
United States
University of Southern California (USC) - Norris Comprehensive Cancer Center
Los Angeles, California, United States
Ocala Oncology
Ocala, Florida, United States
Indiana University Melvan and Bren Simon Cancer Center
Indianapolis, Indiana, United States
The Christ Hospital
Cincinnati, Ohio, United States
Mary Crowley Cancer Research Center
Dallas, Texas, United States
Virginia Cancer Specialists, P.C.
Fairfax, Virginia, United States
Start Date
December 20, 2023
Primary Completion Date
June 30, 2026
Completion Date
December 30, 2026
Last Updated
September 9, 2025
NCT05720117
NCT06898450
NCT05098132
NCT05719558
NCT07477743
NCT06598800
Lead Sponsor
LaNova Medicines Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions